Targeting of T lymphocytes against egf‐receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross‐linking for t‐cell activation

No abstract is available for this paper.

• Publication year

  1993

• Venue

  International Journal of Cancer

• Publication date

  1993-12-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.2910550610PMID 8253530
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human C‐ERBB‐2 proto‐oncogene product as a target for bispecific‐antibody‐directed adoptive tumor immunotherapy

  1992cited by this paper
• EGF receptor amplification and expression in human brain tumours.

  1992cited by this paper
• Epidermal growth factor receptors (EGFR) in human ovarian cancer.

  1991cited by this paper
• Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.

  1991cited by this paper
• Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.

  1991cited by this paper
• Bispecific monoclonal antibodies directed to CD16 and to a tumor‐associated antigen induce target‐cell lysis by resting NK cells and by a subset of NK clones

  1991cited by this paper
• Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).

  1991cited by this paper
• Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.

  1991cited by this paper
• The epidermal growth factor receptor as a target for therapy.

  1990cited by this paper
• Preliminary trial of specific targeting therapy against malignant glioma.

  1990cited by this paper
• Re‐targeting of human lymphocytes expressing the T‐cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies

  1989cited by this paper
• Retargeting of T‐cell‐receptor gamma/delta+ lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production

  1989cited by this paper
• Activation of mononuclear cells to be used for hybrid monoclonal antibody‐induced lysis of human ovarian carcinoma cells

  1988cited by this paper
• A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s)

  1988cited by this paper
• Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

  1987cited by this paper
• The use of hybrid hybridomas to target human cytotoxic T lymphocytes

  1987cited by this paper
• T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies.

  1987cited by this paper
• Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.

  1987cited by this paper
• Bispecific monoclonal antibodies from hybrid hybridomas.

  1986cited by this paper
• High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines.

  1986cited by this paper
• [17] Bispecific monoclonal antibodies from hybrid hybridomas

  1986cited by this paper
• Signal transducing mechanisms involved in human T cell activation via surface T44 molecules. Comparison with signals transduced via the T cell receptor complex

  1986cited by this paper
• Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

  1985cited by this paper
• Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells.

  1984cited by this paper
• Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

  1984cited by this paper
• Hybrid hybridomas and the production of bi-specific monoclonal antibodies.

  1984cited by this paper
• Materials and Methods Brief Definitive Report Triggering T Cells by Otherwise Inert Hybrid Anti-cd3/antitumor Antibodies Requires Encounter with the Specific Target Cell

  year unknowncited by this paper

• Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B.

  2024cites this paper
• Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity

  2020cites this paper
• Human Organotypic Models for Anti-infective Research.

  2018cites this paper
• Repetitive intravenous application of the bispecific antibody BIS-1 in carcinoma patients receiving subcutaneous interleukin-2

  2018cites this paper
• T cell engaging bispecific antibody (T‐BsAb): From technology to therapeutics

  2017cites this paper
• Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system

  2012cites this paper
• CD3-CD28Costimulationas a Meansto AvoidingT CellPreactivationin Bispecific Monoclonal Antibody-based Treatment of Ovarian Carcinoma1

  2006cites this paper
• Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway.

  2005cites this paper
• TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.

  2003cites this paper
• TRANCE-and CD 40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients 1

  2003cites this paper
• Anti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.

  2002cites this paper
• CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma

  1997cites this paper
• CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.

  1997cites this paper
• The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro

  1996cites this paper
• CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.

  1996cites this paper
• T Cell Activation and Cytokine Production in Anti-CD3 Bispecific Antibody Therapy

  1995cites this paper
• Unidirectional potentiation of binding between two anti‐FBP MAbs: Evaluation of involved mechanisms

  1995cites this paper
• Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells

  1995cites this paper
• Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.

  1995cites this paper
• In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.

  1995influential citation
• Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic

  1994cites this paper
• The LFA‐1/ICAM cell adhesion pathway is involved in tumor‐cell lysis mediated by bispecific monoclonal‐antibody‐targeted T lymphocytes

  1994cites this paper